Elevation Oncology

Elevation Oncology reports 2Q 2024 financial results and highlights recent business achievements. “Looking ahead, we remain on track to advance into monotherapy dose expansion and initiate the combination portion of our Phase 1 trial evaluating EO-3021 by year-end, report additional monotherapy data for EO-3021 in the first half of 2025, and nominate a development candidate from our HER3-ADC program in the second half of 2024,” said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology. Full release at https://lnkd.in/e54Wmeid

Elevation Oncology today announced promising initial data from the dose escalation portion of the ongoing Phase 1 clinical trial of EO-3021 in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction (GEJ), pancreatic or esophageal cancers. “We are encouraged to see the benefits of EO-3021's site-specific conjugation translate clinically, with minimal MMAE-associated toxicities observed in our Phase 1 trial. Coupled with the promising anti-tumor activity reported in patients with gastric or GEJ cancer, the data suggest that EO-3021 is a potential best-in-class Claudin 18.2 antibody drug conjugate,” said Valerie Malyvanh Jansen, M.D., Ph.D., Chief Medical Officer of Elevation Oncology. Full release at https://lnkd.in/e3yb_m26

$ELEV CEO Joseph Ferra spoke with Karen Jagoda of the Empowered Patient Podcast to discuss the use of Antibody Drug Conjugates (ADCs) targeting Claudin 18.2 to treat gastric cancer, ongoing clinical trials and the future of ADCs in oncology. Learn how this approach is addressing the high unmet needs in gastric cancer treatment and offering hope for better patient outcomes. Listen to the full episode here: https://lnkd.in/ejmM4eNE #GastricCancer #Oncology #Podcast

We are excited to welcome Dr. Henry Koon to team Elevation, where he will take on the role of Vice President, Clinical Development. Henry is a physician scientist with over 20 years of experience in medical oncology and drug development. Learn more about our team on the website: https://lnkd.in/eMCtzw4C

Happy 4th of July from team Elevation!

Elevation Oncology today announced plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Following recently signed clinical supply agreements with Eli Lilly and Company and GSK, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab and dostarlimab, respectively. "We are excited to begin evaluating EO-3021 together with ramucirumab, a VEGFR2 inhibitor, and with dostarlimab, a PD-1 inhibitor, in the second- and first-line settings, respectively,” said Valerie Malyvanh Jansen, M.D., Ph.D., Chief Medical Officer of Elevation Oncology. Full release at https://lnkd.in/eMFCWzhu

This Juneteenth, Elevation joins in recognizing freedom, resilience, and the enduring spirit of Black Americans. We stand by equality and freedom for all, committed to building a more inclusive future. #Juneteenth

At Elevation, we believe in equal rights to life, freedom, and happiness, regardless of sexual orientation or gender identity. We celebrate the LGBTQIA+ community and equality for all. #PrideMonth #Proud #Equality

Elevation is at #BIO2024! Biren Shah, SVP of Business and Corporate Development, is attending the BIO International Convention 2024 in San Diego. "Looking forward to seeing old friends and evaluating new growth opportunities leveraging Elevation's ADC pipeline,” says Biren. https://lnkd.in/dKrXuHVa

Check out a new episode of the Progress, Potential, And Possibilities podcast where our CEO, Joseph Ferra and CSO, David Dornan, PhD, delve into the current landscape of #ADC space and Elevation’s role in advancing new therapies for cancers. “We are leveraging the latest in ADC technology and our expertise in it to build a differentiated pipeline starting with EO3021 and our second program HER3 ADC,” notes Joseph Ferra. Full episode at https://lnkd.in/eJyrWNuB